Riskpilot← Back to searchSign inGet full accessENDOSIS AB
ABActiveOrg 5593319352Mellanbergsvägen 29Other education n.e.c. · NACE 8559Est. 20210 employees
Revenue 2024
SEK 0
EBITDA margin
—
-50% vs 2023
Equity ratio
44.0%
Financial strength
Net profit 2024
SEK -3K
+63% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -3K | -50% |
| Net profit | SEK -3K | +63% |
| Total assets | SEK 25K | -34% |
| Equity | SEK 11K | -21% |
| Employees | 0 | — |
Legal name
ENDOSIS AB
Org number
5593319352
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
25 augusti 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
verksamhet bedrivs, uppmärksamma och vägleda personer som påverkas i samhället. Företaget ska utbilda i första hand kommuner, vårdenheter, ungdomsmottagningen, skol och hälsovården samt beslutsfattare som möter människor med symtom och diagnos i vardagen och informera kring endometrios och kroniska sjukdomar. Verksamheten ska arbeta aktivt med en hållbar hälsa samt kädkollektion som är specifikt inom endometrios för att uppmärksamma sjukdomen.
Address
Mellanbergsvägen 29
Email
endosis@mail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 43 | 25 | 0 |
| Staff expenses | — | — | — |
| EBITDA | −3 | −2 | −3 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | −3 | −2 | −3 |
| Net financials | −1 | −1 | — |
| Profit before tax | −3 | −3 | −3 |
| Tax | −0 | −5 | −0 |
| Net profit | −3 | −8 | −3 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 28 | 38 | 25 |
| Equity | 22 | 14 | 11 |
| Long-term debt | 1 | 0 | 2 |
| Short-term debt | 5 | 24 | 13 |
| Total debt | 6 | 24 | 15 |
EBITDA margin
-300000.0%
This company
15.8%
Market median
-1898834% vs market
20222024
Equity ratio
44.0%
This company
38.2%
Market median
+15% vs market
20222024
Return on equity
-27.3%
This company
18.4%
Market median
-248% vs market
20222024
Net profit margin
-300000.0%
This company
8.1%
Market median
-3703804% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
1.27×
This company
0.62×
Market median
-105% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LJ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ENDOSIS AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Laila Jassim | Chief Executive Officer | 0 companies |
| Linus Erik Michael Levin | Deputy Board Member | 0 companies |